Immunotherapy for osteosarcoma: Where do we go from here?
Pediatric Blood & Cancer2018Vol. 65(9), pp. e27227–e27227
Citations Over TimeTop 10% of 2018 papers
Abstract
Osteosarcoma is the most common bone tumor in children and young adults, with few advances in survival and treatment, especially for metastatic disease, in the last 30 years. Recently, immunotherapy has begun to show promise in various adult cancers, but the utility of this approach for osteosarcoma remains relatively unexplored. In this review, we outline the mechanisms and status of immunotherapies currently in clinical trials as well as future therapies on the horizon, and discuss their potential application for osteosarcoma.
Related Papers
- → Tumor-Suppressing Effects of miR-141 in Human Osteosarcoma(2013)32 cited
- → Circular RNA circNRIP1 plays oncogenic roles in the progression of osteosarcoma(2021)27 cited
- → Metachronous Osteosarcoma, A Differential Diagnosis to be Considered in Children With Osteosarcoma: A Review of Literature and a Case From Our Center(2022)4 cited
- A experimental study on chemosensitivity to Osteosarcoma in vitro(2013)
- → Atypical Cases of Osteosarcoma.(1991)